ABBOTT LABORATORIES Annual Report, Year Ended Dec 31, 2017

Abbott Laboratories filed its 10-K for the period ending December 30, 2017, detailing a year of significant strategic acquisitions and divestitures. The company completed the acquisition of St. Jude Medical for approximately $23.6 billion and Alere, Inc. for $4.5 billion, substantially expanding its medical device and diagnostics portfolios. Concurrently, Abbott divested its vision care business, Abbott Medical Optics (AMO), to Johnson & Johnson for $4.325 billion, demonstrating a proactive portfolio management strategy. These significant transactions led to an increase in total debt, which stood at approximately $28 billion at year-end 2017. The company's operational performance showed revenue growth driven by these acquisitions, although operating margins were impacted by integration costs and amortization expenses. From an investor's perspective, the report highlights Abbott's transformation into a more diversified healthcare company with strengthened positions in cardiovascular devices and diagnostics. The company remains committed to deleveraging its balance sheet and optimizing its operational structure. Investors should note the company's continued investment in research and development, with approximately $2.2 billion spent in 2017, and its focus on emerging markets for future growth, particularly within its Established Pharmaceutical Products and Nutritional Products segments. The company also continues its practice of returning capital to shareholders through dividends, with an increase declared in the fourth quarter of 2017.